Pfizer

Oct 30, 2024

Neuroendocrine tumors are a complex group of tumors that develop predominantly in the digestive or respiratory tract but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes, causing them to divide u...

Oct 28, 2024

Pfizer’s ABRYSVO became the first and only RSV vaccine approved for use in adults under 50, offering the most extensive RSV vaccine coverage for adults. The label expansion announced on 22 October 2024 includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD). &nb...

Aug 20, 2024

Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has recently achieved a significant milestone with the FDA's approval of AMONDYS 45 (casimersen). This antisense oligonucleotide, developed from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, is now approved for treati...

Dec 05, 2023

FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Merck, operating as MSD internationally, reported that the U.S. Food and Drug Administration (FDA) has prioritized the review of a supplementar...

Nov 27, 2023

The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach cancer, permitting its usage alongside chemotherapy for first-line treatment in patients with locally advanced unresecta...

Nov 21, 2023

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...

Oct 24, 2023

UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...

Oct 20, 2023

Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III resul...

Jul 03, 2023

On 26 June 2023, the rush to develop obesity therapies appeared to have raised the bar, as an experimental weight-loss drug from US pharma company Eli Lilly yielded the greatest effects of any treatment observed thus far. The American Diabetes Association’s annual meeting has brought the competitive dynamics of ...

Jun 27, 2023

FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to decrease blood sugar together with diet and exercise in children 10 years and older w...